EU expands approval of Janssen-Cilag's prostate cancer drug Zytiga

01/15/2013 | PharmaTimes (U.K.)

The European Commission approved the use of Janssen-Cilag's Zytiga, or abiraterone acetate, in combination with prednisolone or prednisone, for patients with metastatic castration-resistant prostate cancer who do not respond to androgen deprivation and for whom chemotherapy is not indicated. The drug's approval in the U.S. was expanded recently to include men with metastatic castration-resistant prostate cancer before chemotherapy.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ